The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients

NCT01052311 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

8

Enrollment

OTHER_GOV

Sponsor class

Stopped The sponsor decided to withdraw study drug from market

Conditions

Coronary Artery Disease
Dyslipidemia

Interventions

DRUG: Tredaptive (1 g extended release niacin+ 20 mg laropiprant)
DRUG: Placebo
DRUG: Tredaptive

Sponsor

Sheba Medical Center